The global gene panels market is expected to reach USD 2.95 Billion by 2023 from USD 1.22 Billion in 2018, at a CAGR of 19.2%. Increasing prevalence of chronic diseases and growing company initiatives are some of the major factors responsible for driving this market.

Agreements, partnerships, joint ventures, and collaboration accounted for the largest share of the overall growth strategies followed by key players between 2015 and 2018. Some of the key players in the gene panels market include Illumina, Inc. (US), BGI (China), Agilent Technologies (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Inc. (US), ), Novogene Corporation (China), F. Hoffmann-La Roche AG (Switzerland), Integrated DNA Technologies (IDT) (US), GATC Biotech AG (GATC Biotech) (Germany), and ArcherDx (US).

Target Audience for this Report:

# NGS equipment manufacturers, vendors, and distributors
# NGS sequencing services companies
# NGS bioinformatics/data analysis companies
# Research institutes and government organizations
# Venture capitalists and government funding organizations
# Research and consulting firms
# Healthcare institutions
# Pharmaceutical and biotechnology companies
# Contract manufacturing organizations
# Contract research organizations

Ask for FREE PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=101282859

Illumina led the global gene panel test kit market in 2017, it is a well-established company and one of the leading brand names in the market. The leading position of the company can be attributed to its exhaustive product portfolio and strong geographic presence. The company focuses on organic as well as inorganic growth strategies to enhance its market position, such as agreements, partnerships, and collaborations that allow it to access the capabilities of complementary businesses and expand geographically. In the last three years, Illumina collaborated with companies such as Thermo Fisher Scientific (2018), Pensabio (2015), and Amoy Diagnostics Co. Ltd. (2015).

The objectives of this study are as follows:

# To define, describe, and forecast the global gene panel market by product & service, technique, design, application, end user, and region.

# To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges).

# To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for the key players.

# To forecast the size of the market with respect to five regions: North America, Europe, Asia Pacific, and the Rest of the World.

# To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.

# To track and analyze competitive developments in the gene panel market, such as agreements, collaborations, acquisitions, product launches, expansions, and R&D activities

Thermo Fisher Scientific is the second-largest player in the gene panel test kits market in 2017. The company adopts organic and inorganic growth strategies to enhance its market share. It is an innovation-centric company and invests heavily in R&D. For example, it spent 4.4% of its revenue in 2017 of R&D activities. This high R&D investment helps the company to introduce and upgrade its products in the market. Some products launched by the company recently are the Ion AmpliSeq On-Demand (2017) and Ion Torrent AmpliSeq RNA Fusion Lung Cancer Research Panel (2015). Product launches help the company to stay current in the market and provide innovative solutions to its end users.

Request for FREE Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=101282859

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]